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Abstract 
Nanocarriers can aid therapeutic agent administration to the lung, but controlling drug 
delivery from these systems after deposition in the airways can be problematic. The aim of 
this study was to evaluate if chemically mediated shell permeabilisation could help 
manipulate the rate and extent of nanocarrier drug release. Rifampicin was loaded into lipid 
shell (loading efficiency 41.0 ± 11.4%, size 50 nm) and polymer shell nanocarriers (loading 
efficiency 25.9 ± 2.3%, size 250 nm). The drug release at pH 7.4 (lung epithelial pH) and 4.2 
(macrophage endosomal pH) with and without the chemical permeabilisers (Pluronic L62D - 
lipid nanocarriers; H+- polymer nanocarriers) was then tested. At pH 7.4 the presence of the 
permeabilisers increased nanocarrier drug release rate (from 3.2 µg/h to 6.8 µg/h for lipid 
shell nanocarriers, 2.3 µg/h to 3.4 µg/h for polymer shell nanocarriers) and drug release 
extent (from 50% to 80% for lipid shell nanocarriers, from 45% to 76% for polymer shell 
nanocarriers). These effects were accompanied by lipid nanocarrier distension (from 50 to 
240 nm) and polymer shell hydrolysis. At pH 4.2 the polymer nanocarriers did not respond to 
the permeabiliser, but the lipid nanocarrier maintained a robust drug release enhancement 
response and hence they demonstrated that manipulation of controlled drug release of lung-
targeted nanocarriers was possible through chemically mediated shell permeabilisation. 
 
 
 
Key words: Lipid nanoparticles; polymer nanoparticles, inhaled drug delivery, rifampicin, 
poly(vinyl alcohol), controlled drug release; dissolution.  
  
3 
 
1. Introduction 
The incorporation of drugs into nanocarriers can enhance their delivery by improving 
the agents chemical stability, water solubility and in-vivo clearance rates (Parveen et al., 2012; 
Peer et al., 2007). However, for nanocarriers to realise these benefits they must be able to 
hold an appropriate amount of an active agent and control its release at the site of delivery. 
The large surface area to volume ratio of nanocarriers can be problematic when attempting to 
control drug release because it renders them highly sensitive to interactions with the bodily 
fluids into which they are delivered. As a consequence, nanocarrier systems have a tendency 
to display an immediate release of their drug payloads (Natarajan et al., 2014). If the initial 
release rate is rapid and it liberates a significant portion of drug in a short period then this can 
negate the potential of the nanocarriers to protect their drug payloads from chemical 
instability and rapid in-vivo clearance (Danhier et al., 2009; Janes et al., 2001).  
Improving the affinity of the drug for the carrier, e.g., by forming ion-pairs in the 
carrier matrix (Holmkvist et al., 2016; Pinkerton et al., 2012), can reduce the immediate 
release effect experienced by some nanocarrier systems and in some cases it can act to sustain 
drug release over several days (Mukherjee et al., 2008). However, paradoxically, such a slow 
release can create another problem, incomplete drug liberation. For therapeutic use, 
nanocarriers must release their payload to produce the target pharmacokinetic profile in a 
timeframe that complements carrier clearance dynamics. The ideal scenario is to use a system 
which allows strong retention of the drug during formulation storage and complete liberation 
upon delivery to provide the desired duration of drug action. This is very difficult to achieve 
inherently and there is a need to develop active release strategies that will control drug 
delivery from nanocarriers upon administration. 
Nanocarriers that change their form in response to an external stimuli provide a 
potential solution to poor drug release by nanocarriers (Mura et al., 2013). Active release can 
be induced in response to the biological environment upon administration or can be achieved 
using specific chemical or physical stimuli (Ganta et al., 2008). In respiratory drug delivery, 
nanocarriers can be co-formulated with trigger agents such that the exogenous chemical agent 
is available to modify drug release after deposition in the airways of the lung. Because 
inhaled products employ micron-sized particles to facilitate deposition (Wang et al., 2012), 
the nanocarrier and the agent used to control drug release can be immobilised in a 
microparticle formulation. Upon inhalation, the microparticle will deposit in the airways and 
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dissolve in the liquid-limited mucosal surface such that the chemical trigger the nanocarrier 
mix at the point of delivery. 
The aim of this study was to assess whether the co-administration of nanocarrier shell 
permeabilisers is a practicable strategy to control drug release from nanocarriers. Two 
nanocarriers with different shell properties were investigated. These were a polymeric shelled 
nanocarrier, constructed with a lipid benzyl benzoate core, a phospholipid intermediate layer 
and an outer poly(vinyl alcohol) (PVA) shell and a lipidic shelled nanocarrier, which 
contained a triglyceride core and a semi-solid phosphatidylcholine / PEG hydroxystearate 
shell. Both the nanocarriers have been shown to be biocompatible with lung airway cells 
(Chana et al., 2015; Madlova et al., 2009) and their safety has been assessed by acute lung 
toxicity testing in mice (Jones et al., 2014). The shell permeabiliser for the lipid nanocarrier 
was a Pluronic surfactant, whereas for the polymer nanocarrier an acidic environment was 
used to hydrolyse the polymer and modify shell permeability. Both these shell permeabilisers 
have been shown to be biocompatible with lung airway cells in previous work (Chana et al., 
2015). As there is a need to localise anti-tuberculosis (TB) drugs in the respiratory system for 
extended periods of time (Sosnik et al., 2010) and previous work had shown burst release was 
a problem for these agents (Ohashi et al., 2009; Pandey et al., 2003), rifampicin was selected 
as the model agent for the study. Previous work with rifampicin has shown that this agent is 
chemically unstable in water and therefore nanocarriers could be particularly beneficial for 
this agent (Singh et al., 2013). To understand better how the model drug would be released 
from the nanocarriers two pH conditions, 7.4 and 4.2 were used in the drug release studies. 
These two particular pHs were selected as they are relevant to environments encountered in 
the lungs, i.e., they mimicked the pH of the airways and lysosomal compartments of alveolar 
macrophages, respectively (Mindell, 2012). The investigation included effect of the chemical 
triggers on the rate and extent of drug release, plus explored how modified release was 
achieved by applying analytical tests to probe nanocarrier shell transformations. 
2. Materials and methods 
2.1. Materials 
 Medium chain triglycerides (Labrafac® lipophile 1349), purified phosphatidylcholine (> 
90 %) from soybean lecithin (Epikuron® 200) and PEG 15 hydroxystearate (Solutol® HS15) 
were kindly supplied by Gattefossé S.A. (Saint- Preist, France), Cargill GmbH (Germany), 
and BASF (Ludwigshafen, Germany), respectively. Pluronic®L62D was sourced from BASF 
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(New Jersey, USA). Poloxamer 188was from BASF (Ludwigshafen, Germany) and Epikuron 
phospholipid was from Cargill GmbH (Germany). Sodium chloride, sodium hydroxide, citric 
acid, sodium citrate, poly(vinyl acetate) (Mw 12800), benzyl benzoate and rifampicin (≥ 97%, 
HPLC) were purchased from Sigma Aldrich (Gillingham, UK). High performance liquid 
chromatography (HPLC) grade water, ethanol and methanol were obtained from Fischer 
Scientific (Leicestershire, UK). 
2.2. Fabrication of lipid shell nanocarriers 
 The lipid shell nanocarriers were manufactured via precipitation from a stable emulsion 
following repeated phase inversion, as described by Heurtault et al (Heurtault et al., 2002). 
Medium chain triglycerides (17% w/w), phosphatidylcholine (1.75% w/w), PEG 
hydroxystearate (17% w/w) and a 3% w/v sodium chloride aqueous solution (64.25% w/w) 
were mixed at room temperature and then heated to 85°C at a rate of 4°C per minute, with 
continuous magnetic stirring. The mixture was then allowed to cool to 60°C. The temperature 
of the mixture was cycled between 60°C and 85°C a total of three times. Within this 
temperature range phase inversion occurred with an oil-in-water emulsion being converted to 
a water-in-oil emulsion. Following the final heating cycle, the emulsion was allowed to cool 
to 72°C, at which point 25 mL of ice-cold water was added, causing nanocarrier generation. 
The suspension was stirred for 5 min and then made up to a final volume of 50 mL using 
deionised water. The lipid shell nanocarrier suspensions were purified of excess excipients 
and larger particulate matter via centrifugation (Beckman L8-80 ultracentrifuge, Beckman 
Coulter, Buckinghamshire, UK) at 110,000 g, 25°C for 1 h. The suspension was separated 
into three distinct layers; an upper gel like layer, a middle lipid shell nanocarrier suspension 
layer, and a bottom sediment layer. The purified suspension layer was used for further 
experimental work. 
2.3. Fabrication of polymer shell nanocarriers 
The synthesis of PVA used to produce the polymer shell nanocarriers was based on 
direct saponification method. PVA32% hydrolysis was produced from a poly(vinyl acetate) 
with the optimal reaction conditions which had previously been published (Chana et al., 
2008). The percentage hydrolysis of the PVA polymer was determined by nuclear magnetic 
resonance (NMR) analysis and calculated according to the previously detailed (Chana et al., 
2008). 
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The polymer shell nanocarriers were fabricated by nanoprecipitation (Madlova et al., 
2009). Briefly citrate buffer was prepared by adding 40 mL of 0.1 M citric acid solution to 60 
mL of 0.1 M sodium citrate solution and adjusted to achieve a pH of 4.8. Poloxamer 188 (0.5 % 
w/v) was added to citrate buffer and made up to a volume of 100 mL. Methanol: water with a 
ratio of 9:1 v/v was used as organic solvent. A mixture of 50 mg PVA and 75 mg of Epikuron 
phospholipid was dissolved in 5 mL and 10 mL of organic solvent respectively. A 0.33 mL 
aliquot of benzyl benzoate was added to the methanol/water mixture to complete the organic 
dispersing phase. To fabricate the nanocarriers, the aqueous phase (30 mL) was homogenized 
at 5000 rpm for 2 min and then 15 mL of the organic phase was added drop-wise, at a speed 
of 8 mm/min, using a syringe pump. The homogenization process was continued for 10 
minutes. The suspension produced was transferred to the fume hood and left to stir 20 h to 
remove the organic solvent. The suspension was centrifuged at 4000 rcf for 5 min at 20 °C to 
remove large particle contamination. 
2.4. Nanocarrier characterization 
The nanocarrier size was analysed using photon correlation spectroscopy (PCS) 
(Zetasizer Nano, Malvern Instruments, Worcestershire, UK). All measurements were carried 
out at a scattering angle of 173° using water as the dispersant (refractive index 1.33, viscosity 
0.8872 cP at 37°C). Each measurement comprised 10-14 runs and was performed in triplicate 
for each sample. Mean diameters obtained from the size-intensity frequency distributions 
were reported. To investigate the effect of suspension concentration on the accuracy of the 
size measurement, and to determine the absolute carrier diameter, analyses were performed 
on nanocarrier suspensions serially diluted with HPLC grade water (n = 3). Mean diameter 
was plotted against suspension concentration, and the y-axis intercept following linear 
regression analysis was determined as the absolute diameter. The zeta potential of the 
nanocarrier was determined by measurement of their electrophoretic mobility (Zetasizer 
Nano, Malvern Instruments, Worcestershire, UK). Samples were analysed following dilution 
with HPLC grade water. Each measurement comprised between 50 to 100 runs and was 
performed in triplicate at 37°C.In order to determine the solid content (mg/mL) of the 
purified nanocarrier suspensions, 0.5 mL aliquots were transferred to Amicon centrifuge 
tubes and spun for 30 min. The nanocarrier collection chambers were removed from the tubes 
and dried in a fume hood until a constant mass of particles collected from the centrifugation 
process was recorded. 
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2.5. HPLC analysis of rifampicin 
HPLC quantification of rifampicin was performed using a Jasco HPLC pump and a 
dual absorbance detector. A reversed-phase C18 column was used (Phenomenex Gemini 5µm 
C18, 250×4.60 mm). UV detection was performed at 335 nm. The mobile phase consisted of 
acetonitrile: PBS buffer (40: 60 % v/v) pH 7.4 at a rate of 1 mL/min. A 20 µL sample was 
injected onto the column for all the analysed samples. Each sample was quantified by 
reference to a calibration curve with a range of 0.1-0.002 mg/mL. The linearity (R2> 0.999), 
the average intra-day precision (1.8 %), inter-day precision (2.4 %), limit of detection and 
limit of quantification (2.5 and 8.4 µg/mL respectively) showed the assay to be fit for use 
(see supplementary data; S1). The drug was thought to be chemically unstable (Singh et al., 
2013) and this was confirmed in this study (see supplementary data; S2), because a range of 
previously published work has failed to mention this issue (Pandey and Khuller, 2005; 
Pandey et al., 2003; Zahoor et al., 2005). 
2.6. Nanocarrier loading 
For lipid shell nanocarriers, rifampicin was incorporated into the carriers by 
dissolving the drug in 2 mL of acetone and then adding the mixture to the triglyceride. The 
acetone was removed by evaporation before continuing with the manufacture protocol. In 
order to try and enhance the interaction between rifampicin and oil, several batches of 
nanocarriers were produced containing the ion-pairing counterions, sodium stearate and 
sodium ethyl acetate in the oil core. The counterions were combined with rifampicin at the 
molar ratio of 1:20 during the manufacture. For the fabrication of drug loaded PVA shell 
nanocarriers, 15 mg of rifampicin was dissolved in the organic phase and the manufacture 
was repeated as previous protocol.  
An Amicon centrifugal device was used to determine the loading efficiency. The 
amount of drug contained in a) the purified suspension as a whole, b) the nanocarriers only 
and c) the continuous phase was assayed. The nanocarriers were separated from the 
continuous phase using Amicon ultra 0.5 centrifugal filter devices with ultracel 100 
membranes (100 kDa molecular weight cut off) (Millipore, UK).  Aliquots of 0.5 mL were 
removed from the purified nanocarrier suspension and placed in the sample reservoir of the 
filter devices and centrifuged for 30 min at 14,000 g at ambient temperature (Biofuge Pico 
centrifuge, Heraeus, Buckinghamshire, UK). During this process any free drug in the 
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continuous phase passed through the filter into the receiver chamber, and the drug loaded 
nanocarriers were retained on the filter. The filtrate was diluted with water and subjected to 
HPLC analysis and the nanocarriers were dissolved in methanol and subjected to HPLC 
analysis. The drug recovery and loading efficiency of the purified nanocarrier suspensions 
were calculated according to equations [1] and [2]: 
Drug recovery =
Mnanocarrier + Mfiltrate
Msuspension      
[1] 
Loading efficiency (%) =
Mnanocarrier
        Minput           
[2] 
Where Msuspension was the mass of drug in the nanocarrier suspension; Mnanocarrier was 
the mass of drug encapsulated into the nanocarrier; Mfiltrate was the mass of drug in aqueous 
filtrate and Minput was the mass of drug added during manufacture. 
 
2.7. Release of rifampicin from the nanocarriers 
To characterize rifampicin release from the lipid shell nanocarriers, the drug 
remaining in the carriers with and without prior exposure to shell permeabiliser Pluronic 
L62D was measured. When the shell permeabliser was used it was mixed with the purified 
nanocarrier suspensions at a Pluronic: nanocarrier ratio of 1:0.5 w/w. The release of 
rifampicin from the lipid shell nanocarriers was determined by dialyzing the nanocarrier 
suspensions against 500 mL PBS buffer adjusted to pH 7.4 or 4.2 (1.6 mg nanocarrier per mL 
buffer) at 37°C. For the PVA shell nanocarriers the suspensions generated by the 
manufacture method were mixed with PBS pH 7.4 in a 1:1 v/v ratio at 37°C and the drug 
release was determined by dialysis. To permeabilise the PVA shell nanocarriers PBS buffer 
pH 4.2 was added to nanocarrier suspension in a 1:1 v/v for 1 min and then mixture was 
transferred to a dialysis bag and dialysed against 500 mL of PBS buffer (0.06 mg nanocarrier 
per mL buffer) at either pH 7.4 or pH 4.2 to determine the drug release. The rifampicin 
solubility was measured to be 1550 μg/mL at pH 7.4 and 750 μg/mL at pH 4.2, thus sink 
conditions were maintained in all the release experiments (total rifampicin loading per 500 
mL was ca.1.2mg). To monitor the drug release from all the nanocarrier experiments 0.5 mL 
aliquots were removed from dialysis tubing containing the suspensions (12-14 kDa molecular 
weight cut off) at a series of pre-determined time points and rifampicin content in the 
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nanocarriers was measured by HPLC (as detailed in the loading assessment method). The 
drug content remaining in the nanocarriers was calculated according to equation [3]: 
Release (%) =
M0– Mt 
M0
[3] 
WhereM0was the mass of drug in nanocarrier at t0 and Mt was the mass of drug in 
nanocarrier at a time point. The drug remaining in both the PVA polymer and lipid shell 
nanocarriers was quantified rather than the drug released into the dialysis solution as previous 
reports had suggested that rifampicin was chemically unstable in aqueous solution (Singh et 
al., 2000). 
2.8. Shell permeabiliser induced changes of the lipid nanocarriers 
Changes in the size of the lipid nanocarries in response the shell permeabiliser were 
measured after the suspensions were exposed to Pluronic surfactant using identical conditions 
as in the release study. At regular intervals between 30 min and 24 h post permeabiliser 
exposure samples were taken from the dialysis tubing where the particles were being 
suspended and the particle size was measured. PCS was also used to study the effect of pH on 
the ability of surfactant to aggregate. Surfactant solutions of 1 to 100 mg/mL were prepared 
in PBS at the two pHs7.4 and 4.2 as used in the release study. The derived count rate of the 
solutions were measured and the critical micelle concentration (CMC) of the surfactant in 
each of the pH conditions was determined by estimating where the two linear models applied 
to the derived count rate data intercepted. The lipid shell nanocarriers were also visualised 
using Transmission electron microscopy (TEM) before and after exposure to the shell 
permeabiliser. The suspension (3 μL) was applied to a Pioloform-coated copper grid and 
allowed to settle for one min. Excess suspension was blotted away with filter paper and the 
grid washed twice over distilled water before negative staining with 3 μL of an aqueous 1% 
uranyl acetate solution. The grids were allowed to dry before examination with a Tecnai T12 
electron microscope (FEI, Oregon, USA). 
2.9. Polymer nanocarrier changes induced by the shell permeabiliser 
The particle size of the polymer shell nanocarriers had been previously determined 
not to change in preliminary work (data not shown) and hence changes in the chemical 
composition of the carrier matrix upon exposure to the shell permeabiliser were characterised 
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using Fourier transform infrared spectroscopy (FTIR) (Perkin Elmer, Beaconsfield, UK). The 
FTIR spectrometer was fitted with a DuraSamplIRII diamond attenuated total reflectance 
attachment (Smiths detection, Warrington, UK). Each sample was applied in its liquid state to 
the diamond and 32 scans were performed to generate the spectra. Peak positions were 
determined using Spectrum One software (version 6).Intensities of peaks referring to O-H 
and C-O bonds were specifically analysed in order to search for changes in the polymer 
hydrolysis over time. Nanocarrier size change before and after the shell permeabliser were 
captured by TEM as described above. 
2.10. Statistical analysis 
SPSS version 20 (IBM, UK) was used for all statistical analyses. The normality 
(Sapiro-Wilk) and homogeneity of variances (Levene’s test) of the data were assessed prior 
to statistical analysis. The release data were analysed statistically using T-test or Mann-
Whitney test. Differences were considered to be statistically significant at a level of P < 0.05. 
3. Results and discussion 
 
3.1. Nanocarrier characterisation 
Polyvinyl acetate was saponified to produce PVA, which was determined to be 32% 
hydrolysed by NMR analysis (see supplementary data; S3). This PVA was used to 
manufacture the polymer shell nanocarriers. PCS size analysis of the purified polymer 
nanocarrier suspensions revealed a unimodal, normally distributed particle population in the 
nanometre size range (see supplementary data; S4). The blank lipid shell nanocarriers and the 
polymer shell nanocarriers had a mean diameter of ca. 50 and 250 nm and a polydispersity 
index of 0.074 ± 0.02 and 0.143 ± 0.02, respectively (Table 1). The lipid shell nanocarriers 
possessed a zeta potential of -3.46 ± 0.60 mV whilst the polymer shell nanocarriers had a zeta 
potential of-0.27 ± 0.45mV. In order to investigate whether the dispersion medium was 
having a significant influence on the PCS data, the particle size measurements were repeated 
upon serial dilution of the nanocarrier suspensions. The size measured upon dilution was 
consistent for the lipid shell nanocarriers over the tested dilution range, the effective diameter, 
i.e. the predicted size at infinite dilution was 49 nm (see supplementary data; S5). However, 
the size of the polymer shell nanocarriers reduced in size upon dilution due to the interference 
of the water soluble stabiliser with the size measurements, hence it gave an effective 
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hydrodynamic diameter of 204 nm (see supplementary data; S5). The size and polydispersity 
of the nanocarriers employed in this work were consistent with those previously reported 
using similar preparation methods (Chana et al., 2015; Madlova et al., 2009). The emulsion-
precipitation method of nanocarrier fabrication was shown to generate a much higher 
nanocarrier solid content compared to the injection-precipitation method (Table 1). 
Table 1: Size, polydispersity, zeta potential and solid content for non-loaded (blank) and 
rifampicin-loaded lipid nanocarriers (LNC) and poly(vinyl alcohol) (PVA) polymer 
nanocarriers. *Measured at a nanocarrier concentration of 80 mg/mL and 3 mg/mL for lipid 
and polymer nanocarriers respectively. Data represent mean ± standard deviation (n = 3). 
Nanocarrier type Mean size* 
(nm) 
Polydispersity* 
index 
Zeta 
potential*(mV) 
Solid content 
(mg/mL) 
LNCblank 52 ± 2 0.07 ± 0.02 -3.46 ± 0.60 146.7 ± 12.2 
LNCrifampicin 50 ± 3 0.07 ± 0.02 -2.07 ± 0.62 163.3 ± 7.0 
PVAblank 249 ± 5 0.14 ± 0.02 -0.27 ± 0.45 5.9 ± 1.5 
PVArifampicin 261 ± 7 0.22 ± 0.02 -0.26 ± 0.37 6.0 ± 0.9 
3.2. Lipid nanocarrier drug release 
Rifampicin loaded into the lipid nanocarriers with a loading efficiency, 41.0 ± 11.4%. 
Drug recovery (mass balance) in the loading determinations was >90%. Continuous passive 
release from the lipid nanocarriers was observed over 24 h at both pH 7.4 (A) and pH 4.2 (C) 
(Fig.1). This continuous release, which presumably commenced immediately after 
manufacture, required the release testing be performed at an identical time post manufacture 
in all the studies. This strategy led to acceptable intra-batch variability across the 
experiments. Attempts to reduce the passive drug release, using an ion-pairing strategy to 
retain the drug in the oil, were unsuccessful (Fig.2). Ion-pairing was employed in this work 
because it has been used previously to improve the retention of hydrophilic drugs in a lipid 
matrix nanocarrier (Zhao et al., 2016) and it has been shown to modify drug release kinetics 
without changing the chemical structure of the drug (Song et al., 2016). However, this 
strategy has not been previously applied to modify the drug release of rifampicin from 
nanocarriers. Theoretically, rifampicin and the counterions are fully ionized in acidic 
conditions enabling ion-pairs to form during the nanocarrier manufacturing process. In 
addition, the hydrophobicity of the complex should increase as the counterions (log P: ethyl 
acetate 0.28, stearate 3.62, calculated by Marvin Sketch, ChenAxon Ltd, Hungary) should 
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produce an ion-paired complex with reduced polarity compared to the parent drug and greater 
affinity for lipid nanocarrier oil core. Therefore, the inability of the counterions used in this 
work to slow rifampicin diffusion out of the nanocarriers was thought to be because 
rifampicin did not effectively form ion pairs in the nanocarrier. This may have been because 
the drug localised at the oil core-nanocapsule shell interface whereas the counterions located 
in the oil core, or because steric hindrance arising from the molecular structure 
incompatibility that prevented ion-pair formation. 
 
Fig.1.Percentage drug release of rifampicin from the lipid nanocarriers with and without the 
co-administration of the shell permeabiliser, Pluronic L62D 1:0.5 w/w, in (A) PBS buffer pH 
7.4 and (C) PBS buffer pH 4.2. Graph (B) and (D) show the corresponding amount of 
rifampicin within the particles versus time fitted with a linear model. Data represent mean ± 
standard deviation (n = 3). 
Although an inherent continuous drug release from the control lipid nanocarriers 
occurred, i.e., without the addition of the permeabiliser, there was still a significant increase 
in the extent of release at each time point when the shell permeabilisers were added to the 
nanocarriers at pH 7.4 (P<0.05). The drug release rate (k) for the lipid nanocarrier in the 
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presence of the shell permeabiliser was double that of the control system (P<0.05), with the 
control and permeabilised nanocarriers releasing approximate 50% and 80% of their 
rifampicin load over 24 h. At pH 4.2 the significant difference in release rate (P<0.05) when 
the permeabilised and non-permeabilised nanocarrier test systems were compared was still 
evident. The rate of drug release from the control nanocarriers at pH 4.2 and pH 7.4 was very 
similar at 3.2 µg/h and 3.0 µg/h respectively despite the lower aqueous solubility of 
rifampicin at pH 4.2 (0.75 mg/mL). This signified that the lipid shell was exerting a good 
degree of control over fluid ingress and drug release. 
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 Non permeabilised
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Fig.2. Rifampicin (RIF) release from lipid nanocarriers after 24 h in phosphate buffered 
saline at pH 7.4 when rifampicin was formulated as the base or ion paired with ethyl acetate 
(EtOAc) or stearate. Permeabilised lipid nanocarriers release was achieved by the addition of 
PluronicL62D.Data represent mean ± standard deviation (n = 3). 
Regardless of whether or not the nanocarrier shells were permeabilised, the lipid 
nanocarrier drug release showed zero order kinetics (Fig 1 B, D) and this matched previous 
reports of drug release from lipidic nanomaterials (Abdel-Mottaleb et al., 2010; Zhai et al., 
2014). Zero-order release suggested that rifampicin was encapsulated by the lipid shell of the 
nanocarrier. However, the release of rifampicin was much more higher compared to that 
previously reported (< 5% release after 24 h) for rhodamine using the same carrier system 
(Chana et al., 2015). The difference in the release profiles was most probably driven by the 
different physicochemical properties of the nanocarrier payloads. Rifampicin has pKas of 1.7 
and 7.9 and a Log P of 1.1(Bhise et al., 2010) whereas rhodamine has a pKa of 4.2 and log P 
of 2.7 (Lahnstein et al., 2008), hence rhodamine should naturally display a higher affinity to 
the oil core of the nanocarriers. 
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Although a continuous release from the lipid shell nanocarrier was observed, there 
was no initial burst release. There is not a standard method that is used to determine burst 
release from nanocarriers, so in this study the % of drug release at t=0.5 h was used as a 
measure of bust release. The lipid shell nanocarriers showed a 5% release at t=0.5 h, whereas 
previous studies using nanocarriers typically cite an initial release of up to 30-40% when 
reporting problems with burst release (Nayak et al., 2010). 
3.3. Polymer shell nanocarrier drug release 
The drug loading in the polymer shell nanocarrier was 25.9 ± 2.3%. At pH 7.4 
continuous drug release (k=2.3 µg/h) was observed, which was enhanced upon exposure to 
the shell permeabiliser (k=3.4 µg/h) (P<0.05, Fig.3). At 0.5 h a 10% release was recorded, 
which was much lower than previous reports of up 80% burst release over a similar time 
frame with a polymer nanocarriers (Sabzevari et al., 2013). Almost 80% of drug came out the 
polymer nanocarriers, which were subject to permeabilisation over 8 h, this was nearly 
double the non-permeabilised system (P<0.05). When the release study was repeated in the 
pH 4.2 medium similar profiles were observed with and without the permeabiliser. There was 
no significant difference in k across the two different pH experiments for the nanocarriers in 
the absence of the shell permeabilisers (P>0.05, Fig.3). 
Several new polymeric nanoparticle technologies have been investigated recently for 
drug delivery applications. These include porous nanoparticle-aggregate particles, dynamic 
pH responsive nanoparticles and self-assembling nanoparticles, but the use of these systems 
in pharmaceutical products has been limited by scale up and toxicity concerns (Kean and 
Thanou, 2010). PVA is a water soluble synthetic polymer that is formed by full or partial 
hydrolysis of poly(vinyl acetate) (PVAc). PVA has proven to be safe as a coating agent for 
pharmaceutical and dietary supplement products, it has good compatibility with lung cells 
and in comparison to other polymeric systems it has a limited potential to cause local lung 
inflammation (DeMerlis and Schoneker, 2003). Furthermore, the production of the 
nanocarriers using PVA is easily scalable. Therefore, this material is well suited to the 
formation of nanocarriers for clinical applications (Madlova et al., 2009). The amphiphilic 
grades of the polymer (30–60% hydrolysis), are the most interesting in terms of drug delivery 
due to their biocompatibility and amphiphilic properties, but they are not readily available. 
Therefore, PVA was synthesised in this study to attain a degree of hydrolysis that would 
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spontaneously generate nanocarriers in an aqueous solution (Chana et al., 2008; Madlova et 
al., 2009). 
 
Fig.3. Release of rifampicin from polymer shell nanocarriers in (A) PBS buffer pH 7.4 and (C) 
PBS buffer pH 4.2.Graph (B) and (D) show the application of a linear model to the drug 
release data. Data were shown as mean ± standard deviation (n = 3). 
It is generally assumed that the main release process from polymeric nanocarriers is 
diffusion through the polymer matrix, but release can also be facilitated by polymer 
degradation (Soppimath et al., 2001). In the case of the polymer nanocarriers in this work the 
drug is placed in an oil core that is coated with the polymer and therefore the release from the 
carrier requires diffusion of the drug through the polymeric shell. This mechanism is 
consistent with the zero-order kinetics observed in this study. 
It was unexpected that at pH 4.2 medium, the rate of drug release was not enhanced 
by the permeabiliser. This result suggested that another factor was confounding the enhanced 
drug release at this acidic pH. The lower aqueous solubility at pH 4.2 compared to pH 7.4 
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could have been one factor responsible for different release characteristics at the more acidic 
pH. However, the fact that this pH dependant change in solubility appeared to influence the 
release from the polymer systems more that the lipid system also suggested that perhaps the 
polymer nanocarriers were more susceptible to water ingress compared to the lipid shell 
carriers. 
3.4. Permeabilisation mechanism for lipid shell nanocarriers 
The exposure of lipid shell nanocarriers to the Pluronic surfactant permeabiliser at pH 
7.4 induced a substantial increase in the carrier size over time (P<0.05), resulting in a mean 
size of 240 ± 1 nm at 24 h (Fig.4). TEM images of control lipid nanocarrier suspensions 
revealed the presence of spherical particles in the 50 nm size range (Fig.5). Following an 8 
hour exposure to Pluronic L62D at pH 7.4 the lipid shell nanocarriers were larger (~200 nm), 
which agreed with the light scattering data (Fig.4). This nanocarrier permeabilisation process 
at pH 7.4 was similar to that previous work (Chana et al., 2015). However, previously the 
size changes of the lipid nanocarriers in acidic dissolution media had not been reported and 
this study showed that no size change occurred at pH 4.2 compared to control nanocarriers. 
The light scattering data revealed that the Pluronic L62D surfactant displayed a significantly 
lower CMC (8.1 ± 1.4) at pH 4.2 compared to pH 7.4 (25.2 ± 2.1) (Fig.4) (P<0.05), indicating 
the greater propensity for the surfactant to aggregate in the more acidic pH medium, thus a 
lower propensity to interact with the nanocarriers. 
For Pluronics with intermediate PO block lengths, such as the grade used in this study, 
insertion into bilayers is the primary means of membrane interaction. The external semisolid 
shell of the lipid nanocarriers was composed of phospholipid, thus Pluronic was expected to 
interact with the shell in a similar manner to a lipid bi-layer, i.e., inserting into the later with 
the two EO segments of the surfactant residing on the apical side of the membrane and the 
PO chain protruding into the hydrophobic domain (Firestone et al., 2003). The pH-dependent 
swelling responses to Pluronic L62D supported the shell insertion mechanism of action 
because the increased propensity for the PEO-PPO-PEO block copolymer to aggregate in the 
aqueous solution would diminish its affinity for the nanocarrier shell surface (Mao et al., 
2001). Although previous work has shown that the Pluronic PEO block can be degraded in 
strong acids, at pH 4.2, this effect was not expected to be as significant as the change in CMC 
demonstrated using the light scattering data (Yang et al., 2006). 
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Fig.4. Lipid nanocarrier distension over time following exposure to the shell permeabiliser 
Pluronic L62D at (A) pH 7.4 and (B) 4.2.Critical micelle concentration (CMC) of Pluronic 
L62D at (C) pH 7.4 and (D) 4.2.Data represent mean ± standard deviation (n = 3). 
 
Fig.5. Transmission electron microscopy (TEM) images of lipid shell nanocarrier suspensions 
(A) before exposure to Pluronic L62D surfactant (80 mg/mL), (B) 8 h after exposure to the 
Pluronic L62D surfactant at pH 7.4. 
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3.5. Permeabilisation mechanism for the polymer shell nanocarriers 
FTIR chemical analysis of the polymer shell nanocarriers showed that there was no 
difference in the intensity of OH peak over time when they were not exposed to the shell 
permeabiliser (Fig.6), which suggested the polymer’s structure was unchanged. For the 
nanocarrier exposed to the shell permeabilising acidic conditions, the intensity of hydroxyl 
group increased over time. TEM showed that the shell permeabliser had no effect on particle 
sizeor the ingress of stain to the nanocapsule core as illustrated in Fig.7. These results suggest 
the mechanism of permeablisation in this dynamic nanosystem was polymer modification via 
carboxyl functional group hydrolysis caused by the acidic conditions. 
 
Fig.6. FTIR spectra for polymer shell nanocarriers permeabilised by (A) buffer pH 7.4 and (B) 
buffer pH 4.2. Regions of interest were the OH stretching region (3700-3200 cm-1) and the C-
O stretching region (1200-1000 cm-1).   
 
Fig.7.Transmission electron microscopy (TEM) images of (A) non non-
permeabilisedpolymer shell nanocarriers and (B) polymer nanocarriers permeabilised by the 
addition of an acid solution. 
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It is well known that ester group of PVA can be hydrolysed to an alcohol under acidic 
conditions (Clayden et al., 2012). Increasing the amount of hydroxyl groups would enhance 
the affinity of the polymer membrane to water and increase surface film solvation, which 
would facilitate drug release via diffusion through membrane pores. The acid solution 
induced the polymer hydrolysis within 1 h, which was similar to the time frame of polymer 
hydrolysis used to generate the polymers. It is also possible that the polymers molecular 
weight can be reduced due to hydrolysis which could facilitate drug release (Xu and Du, 
2003). However, in the time frame of the release experiments it was thought that an increase 
PVA film hydration was most probably the primary cause of the increase in drug release 
because the kinetics of polymer degradation is much slower than that of the hydrolysis 
reaction. The fact that the polymer was hydrolysed upon incubation in a pH 4.2 solution 
supported the notion that the lower aqueous drug solubility at pH 4.2 compared to pH 7.4 was 
responsible for inability for the permeabiliser to improve drug release at the acidic pH rather 
than any effects elicited by the nanocarrier structure. 
4. Conclusions 
Rifampicin loaded lipid shell nanocarriers and polymer shell nanocarriers both 
provided controlled zero order drug release. The carriers controlled release primarily through 
their outer shells. As a consequence, when the nanocarrier shells were permeabilised greater 
quantities of drug diffused out of the carriers. The lipid nanocarriers were permeabilised 
using a Pluronic surfactant, which inserted into the outer shell, whereas the polymer carriers 
were permeabilised through polymer hydrolysis. Both these release mechanisms were 
effective in an environment at 7.4, but at pH 4.2the permeabilisation was only effective for 
lipid nanocarriers. The loading capacity and their ability to increase in size, which could 
improve macrophage targeting, and their ability to have their drug release manipulated by 
shell permeabilisers at pH 4.2 and pH 7.4renders the lipid nanocarriers a very interesting 
system to facilitate drug delivery to the lung.  
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